{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Hodgkin+Lymphoma&page=2",
    "query": {
      "condition": "Advanced Hodgkin Lymphoma",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Advanced+Hodgkin+Lymphoma&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T13:29:38.813Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04681105",
      "title": "Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Recurrent Acute Leukemia",
        "Recurrent B Acute Lymphoblastic Leukemia",
        "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Recurrent Hairy Cell Leukemia",
        "Recurrent Hematologic Malignancy",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent T Acute Lymphoblastic Leukemia",
        "Refractory Acute Leukemia",
        "Refractory B Acute Lymphoblastic Leukemia",
        "Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm",
        "Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
        "Refractory Hairy Cell Leukemia",
        "Refractory Hematologic Malignancy",
        "Refractory Hodgkin Lymphoma",
        "Refractory T Acute Lymphoblastic Leukemia",
        "Systemic Mastocytosis"
      ],
      "interventions": [
        {
          "name": "Acetaminophen",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Diphenhydramine",
          "type": "DRUG"
        },
        {
          "name": "Flotetuzumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ibuprofen",
          "type": "DRUG"
        },
        {
          "name": "Ranitidine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2020-11-18",
      "completion_date": "2025-08-05",
      "has_results": false,
      "last_update_posted_date": "2026-01-28",
      "last_synced_at": "2026-07-23T13:29:38.813Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04681105"
    },
    {
      "nct_id": "NCT00352443",
      "title": "S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "everolimus",
          "type": "DRUG"
        },
        {
          "name": "lapatinib ditosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 66,
      "start_date": "2006-09",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2015-03-06",
      "last_synced_at": "2026-07-23T13:29:38.813Z",
      "location_count": 6,
      "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 3 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00352443"
    },
    {
      "nct_id": "NCT00141297",
      "title": "A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neoplasms",
        "Lymphoma, Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "PD-0332991",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 74,
      "start_date": "2004-09",
      "completion_date": "2014-12",
      "has_results": true,
      "last_update_posted_date": "2016-01-05",
      "last_synced_at": "2026-07-23T13:29:38.813Z",
      "location_count": 4,
      "location_summary": "Detroit, Michigan • New York, New York • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00141297"
    },
    {
      "nct_id": "NCT03526250",
      "title": "Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Recurrent Childhood Ependymoma",
        "Recurrent Ewing Sarcoma",
        "Recurrent Glioma",
        "Recurrent Hepatoblastoma",
        "Recurrent Kidney Wilms Tumor",
        "Recurrent Langerhans Cell Histiocytosis",
        "Recurrent Malignant Germ Cell Tumor",
        "Recurrent Malignant Glioma",
        "Recurrent Medulloblastoma",
        "Recurrent Neuroblastoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Osteosarcoma",
        "Recurrent Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Rhabdoid Tumor",
        "Recurrent Rhabdomyosarcoma",
        "Recurrent Soft Tissue Sarcoma",
        "Refractory Ependymoma",
        "Refractory Ewing Sarcoma",
        "Refractory Glioma",
        "Refractory Hepatoblastoma",
        "Refractory Langerhans Cell Histiocytosis",
        "Refractory Malignant Germ Cell Tumor",
        "Refractory Malignant Glioma",
        "Refractory Medulloblastoma",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Osteosarcoma",
        "Refractory Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Rhabdoid Tumor",
        "Refractory Rhabdomyosarcoma",
        "Refractory Soft Tissue Sarcoma"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Palbociclib",
          "type": "DRUG"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "12 Months to 21 Years"
      },
      "enrollment_count": 23,
      "start_date": "2018-08-13",
      "completion_date": "2024-09-30",
      "has_results": true,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-07-23T13:29:38.813Z",
      "location_count": 115,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 93 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03526250"
    },
    {
      "nct_id": "NCT00002691",
      "title": "Combination Chemotherapy in Treating Pediatric Patients With Stage III or IV Non-Hodgkin's Lymphoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "asparaginase",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "cytarabine",
          "type": "DRUG"
        },
        {
          "name": "daunorubicin hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "etoposide",
          "type": "DRUG"
        },
        {
          "name": "leucovorin calcium",
          "type": "DRUG"
        },
        {
          "name": "mesna",
          "type": "DRUG"
        },
        {
          "name": "methotrexate",
          "type": "DRUG"
        },
        {
          "name": "vincristine sulfate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": null,
      "start_date": "1995-08",
      "completion_date": "2000-06",
      "has_results": false,
      "last_update_posted_date": "2013-06-25",
      "last_synced_at": "2026-07-23T13:29:38.813Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002691"
    },
    {
      "nct_id": "NCT00471367",
      "title": "Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "NHL",
        "Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "AZD4877",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 44,
      "start_date": "2007-04",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2009-09-24",
      "last_synced_at": "2026-07-23T13:29:38.813Z",
      "location_count": 3,
      "location_summary": "New York, New York • Philadelphia, Pennsylvania • Greenville, South Carolina",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00471367"
    },
    {
      "nct_id": "NCT00004212",
      "title": "DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Brain and Central Nervous System Tumors",
        "Lymphoma",
        "Unspecified Childhood Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "exatecan mesylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": null,
      "start_date": "1999-09",
      "completion_date": "2004-04",
      "has_results": false,
      "last_update_posted_date": "2012-05-16",
      "last_synced_at": "2026-07-23T13:29:38.813Z",
      "location_count": 4,
      "location_summary": "New York, New York • Memphis, Tennessee • Dallas, Texas + 1 more",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004212"
    },
    {
      "nct_id": "NCT02954406",
      "title": "A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma, Non-Hodgkin"
      ],
      "interventions": [
        {
          "name": "TAK-659",
          "type": "DRUG"
        },
        {
          "name": "Bendamustine",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "Lenalidomide",
          "type": "DRUG"
        },
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Millennium Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2017-03-05",
      "completion_date": "2020-07-27",
      "has_results": true,
      "last_update_posted_date": "2022-02-18",
      "last_synced_at": "2026-07-23T13:29:38.813Z",
      "location_count": 11,
      "location_summary": "Tucson, Arizona • La Jolla, California • West Hollywood, California + 8 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02954406"
    },
    {
      "nct_id": "NCT00006221",
      "title": "BMS-247550 in Treating Patients With Advanced Cancers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Small Intestine Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "ixabepilone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2000-11",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-11",
      "last_synced_at": "2026-07-23T13:29:38.813Z",
      "location_count": 3,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006221"
    },
    {
      "nct_id": "NCT00004189",
      "title": "Rebeccamycin Analog and Cisplatin With or Without Filgrastim in Treating Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Lymphoma",
        "Small Intestine Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "becatecarin",
          "type": "DRUG"
        },
        {
          "name": "cisplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "1999-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-02-11",
      "last_synced_at": "2026-07-23T13:29:38.813Z",
      "location_count": 3,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004189"
    }
  ]
}